Showing results (761-770 of 1,838) with videos related to

Sort By:
Pageof 184
ESMO Open|May 4, 2024
The long and winding road to biomarkers for immunotherapy: a retrospective analysis of samples from patients with triple-negative breast cancer treated with pembrolizumabL Buisseret, Y Bareche, D Venet, et al.
ESMO Open|May 1, 2024
Prognostic value of EndoPredict test in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative primary breast cancer screened for the randomized, double-blind, phase III UNIRAD trialF Penault-Llorca, F Dalenc, S Chabaud, et al.
ESMO Open|June 7, 2024
Anaemia is independently associated with mortality in patients with hepatocellular carcinomaT Meischl, L Balcar, Y-R Park, et al.
ESMO Open|June 4, 2024
Sunitinib for the treatment of metastatic gastrointestinal stromal tumors: the effect of TDM-guided dose optimization on clinical outcomesE L Giraud, K Westerdijk, M B A van der Kleij, et al.
ESMO Open|June 4, 2024
Phase Ib dose-escalation trial of taselisib (GDC-0032) in combination with HER2-directed therapies in patients with advanced HER2+ breast cancerA Grinshpun, S Ren, N Graham, et al.
ESMO Open|May 14, 2024
An investigation of the clinical impact and therapeutic relevance of a DNA damage immune response (DDIR) signature in patients with advanced gastroesophageal adenocarcinomaM A Baxter, L C Spender, D Cairns, et al.
ESMO Open|May 14, 2024
First-line avelumab treatment in patients with metastatic Merkel cell carcinoma: 4-year follow-up from part B of the JAVELIN Merkel 200 studyS P D'Angelo, C Lebbé, L Mortier, et al.
ESMO Open|May 14, 2024
Evaluation of the inflammation-based modified Glasgow Prognostic Score (mGPS) as a prognostic and predictive biomarker in patients with metastatic colorectal cancer receiving first-line chemotherapy: a post hoc analysis of the randomized phase III XELAVIRI trial (AIO KRK0110)M Boukovala, D P Modest, I Ricard, et al.
ESMO Open|April 18, 2024
The efficacy of sacituzumab govitecan and trastuzumab deruxtecan on stable and active brain metastases in metastatic breast cancer patients-a multicenter real-world analysisD Dannehl, D Jakob, F Mergel, et al.
ESMO Open|April 13, 2024
Open questions, current challenges, and future perspectives in targeting human epidermal growth factor receptor 2-low breast cancerG Curigliano, R Dent, H Earle, et al.
Pageof 184